ARA-290 (Cibinetide)

ARA-290 is an 11-amino-acid synthetic peptide carved from the helix-B surface of EPO — it carries the tissue-protective signaling of erythropoietin without binding the receptor that makes red blood cells. Mechanistically, it is the closest published peptide to "small-fiber peripheral neuropathy targeting": Araim Pharmaceuticals' lead trial (Heij 2012, n=22 sarcoidosis-associated small-fiber neuropathy patients) showed modest but real pain + autonomic-symptom reduction at 4 mg SubQ daily × 28 days. For Dylan's cubital tunnel: WATCH-LIST. The mechanism (IRR agonism at injured peripheral nerve sites) is genuinely aligned with cubital-tunnel pathology, and the EPO-without-erythropoiesis safety distinction is real and well-validated across 15+ years of trial work — but BPC-157 + TB-500 already cover this territory with deeper evidence, larger community use, and better sourcing reliability. Add ARA-290 only if the first BPC-157 + TB-500 cycle produces partial-only response, or revisit if Araim publishes a peripheral-nerve-compression Phase 3 readout.

What ARA-290 is

ARA-290 is cibinetide — the development name used by Araim Pharmaceuticals (Tarrytown, NY) for an 11-amino-acid synthetic peptide derived from the helix-B surface of erythropoietin (EPO). The sequence is pyroGlu-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser (often written QEQLERALNSS, with the N-terminal Q as pyroglutamate for serum stability), molecular weight ~1257 Da. The molecule is also called Helix B Surface Peptide (HBSP) in academic literature, and pHBSP when the pyroglutamate-stabilized form is meant specifically.

The defining biological insight that produced ARA-290 was the recognition that EPO has two distinct receptor systems:

1. The classical EPOR homodimer — two copies of the EPO receptor, expressed on bone marrow erythroid progenitor cells. This is the receptor that drives red-blood-cell production. Activation here is what makes recombinant EPO useful in chronic kidney disease anemia and what gets abused as a doping agent in endurance sport — and it is also what causes EPO's off-target risks: thrombosis, hypertension, increased hematocrit-related stroke risk, pure red-cell aplasia.
2. The innate repair receptor (IRR) — a heterocomplex of one EPOR subunit + one βCR (β-common receptor, CD131) subunit, expressed in many non-erythroid tissues including peripheral nerves, vascular endothelium, cardiac muscle, retina, kidney tubules, and immune cells at sites of injury. This receptor is upregulated specifically in damaged or stressed tissue and is the receptor that mediates EPO's tissue-protective and repair-signaling effects — which had long been observed clinically (EPO patients with stroke or MI had better outcomes than expected) but were impossible to use therapeutically because the erythropoietic effect dominates the dose-response curve.

The Brines/Cerami group (Anthony Cerami, the discoverer of TNF-α biology and co-founder of Araim) mapped out which residues of EPO bind which receptor and discovered that the outer surface of helix B carries the IRR-binding motif but lacks the residues required for EPOR-homodimer activation. The 11-AA peptide they designed reproduces the IRR signal without the erythropoietic signal — this is the central pharmacological premise of ARA-290 and the key safety distinction from EPO itself.

The IRR receptor and downstream cascades

When ARA-290 binds the IRR (EPOR/βCR heterocomplex) at sites of tissue injury, it activates a network of repair-relevant intracellular cascades:

1. JAK2-STAT3 and JAK2-STAT5 signaling. Drives transcription of anti-inflammatory and anti-apoptotic genes; suppresses NF-κB-driven inflammatory cytokine output (TNF-α, IL-6, IL-1β reductions documented in multiple in vitro and rodent injury models).
2. PI3K-Akt pathway. Pro-survival signaling — reduces injured-cell apoptosis, supports mitochondrial integrity, drives metabolic recovery in stressed tissue. Particularly relevant for injured peripheral nerves where Schwann cells and axons are under metabolic stress at compression sites.
3. ERK1/2 (MAPK) pathway. Cell-proliferation and migration signaling — supports the neurogenic/regenerative arm of nerve recovery.
4. eNOS activation + endothelial cytoprotection. Increases vascular nitric oxide bioavailability at injury sites, supports microcirculation in compromised tissue (mechanism overlap with BPC-157's NO-system modulation, though BPC-157 acts primarily through VEGFR2 + iNOS modulation rather than through the IRR).
5. Mitochondrial preservation. ARA-290 has demonstrated preservation of mitochondrial membrane potential in rodent ischemia-reperfusion and oxidative-stress models — a downstream consequence of Akt-mediated stabilization of Bcl-2 family pro-survival proteins.
6. Macrophage polarization toward M2 (resolution-phase). Shifts injured-tissue immune environment from acute pro-inflammatory M1 toward anti-inflammatory / pro-repair M2 macrophage phenotype — relevant for chronic compression injury where ongoing low-grade M1 activity maintains the pathology.

Specifically for peripheral nerves and small-fiber neuropathy

The mechanism that maps onto Dylan's cubital tunnel is the small-fiber peripheral-nerve regeneration signal documented in the published Araim work and rodent models:

• Small-fiber neuropathy (SFN) is degeneration or dysfunction of the small unmyelinated C-fibers and lightly myelinated Aδ-fibers — the fibers that carry pain, temperature, and autonomic signals. Classic symptoms: burning pain, tingling, numbness, occasional autonomic complaints (sweating, orthostasis). Sarcoidosis-associated SFN is the indication where ARA-290 has its strongest published human data.
• Cubital tunnel chronic compression primarily produces large-fiber demyelination (motor/sensory dysfunction in the ulnar distribution), but chronic compression also drives small-fiber damage — the burning, tingling, and pressure-pain qualities Dylan describes are partially small-fiber-mediated. This is why ARA-290's mechanism is more cubital-tunnel-relevant than its label-indication (sarcoidosis-SFN) might suggest at first read.
• Animal data for peripheral nerve injury: Sciatic nerve crush, axotomy, and chemotherapy-induced neuropathy models in rats and mice show ARA-290 treatment produces faster nerve-fiber density recovery in skin biopsies, improved nerve conduction velocity, reduced mechanical allodynia, and reduced neuropathic pain behaviors. This is the rodent evidence base that supports extrapolation to cubital tunnel.
• Schwann-cell support is part of the mechanism but less direct than BPC-157's specific Schwann-migration support — ARA-290 is more about anti-inflammatory + small-fiber-axonal-survival signaling than about Schwann-cell mobilization.

Plain English summary

ARA-290 is a piece of EPO that does the "tissue protection" half without doing the "make red blood cells" half. The tissue-protection signal works through a different receptor (IRR) that's only switched on in damaged tissue. The compound calms inflammation, supports injured cells' mitochondria, and helps damaged peripheral nerve fibers — especially the small ones that carry burning and tingling — recover. For cubital tunnel, this means the mechanism is targeting one specific component of the pathology (small-fiber damage at the chronic compression site) that BPC-157 and TB-500 hit indirectly. The added value over BPC-157 + TB-500 is uncertain.